Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 143

1.

Contributions of metabolic dysregulation and inflammation to nonalcoholic steatohepatitis, hepatic fibrosis, and cancer.

Lade A, Noon LA, Friedman SL.

Curr Opin Oncol. 2014 Jan;26(1):100-7. doi: 10.1097/CCO.0000000000000042. Review.

2.

Challenges and Management of Liver Cirrhosis: Practical Issues in the Therapy of Patients with Cirrhosis due to NAFLD and NASH.

Traussnigg S, Kienbacher C, Halilbasic E, Rechling C, Kazemi-Shirazi L, Hofer H, Munda P, Trauner M.

Dig Dis. 2015;33(4):598-607. doi: 10.1159/000375353. Epub 2015 Jul 6. Review.

PMID:
26159280
3.

Nonalcoholic fatty liver disease and hepatocellular carcinoma: a weighty connection.

Starley BQ, Calcagno CJ, Harrison SA.

Hepatology. 2010 May;51(5):1820-32. doi: 10.1002/hep.23594. Review.

PMID:
20432259
4.

Obesity-induced gut microbial metabolite promotes liver cancer through senescence secretome.

Yoshimoto S, Loo TM, Atarashi K, Kanda H, Sato S, Oyadomari S, Iwakura Y, Oshima K, Morita H, Hattori M, Honda K, Ishikawa Y, Hara E, Ohtani N.

Nature. 2013 Jul 4;499(7456):97-101. doi: 10.1038/nature12347. Epub 2013 Jun 26. Erratum in: Nature. 2014 Feb 20;506(7488):396. Hattori, Masahisa [corrected to Hattori, Masahira].

PMID:
23803760
5.

NAFLD leads to liver cancer: do we have sufficient evidence?

Duan XY, Zhang L, Fan JG, Qiao L.

Cancer Lett. 2014 Apr 10;345(2):230-4. doi: 10.1016/j.canlet.2013.07.033. Epub 2013 Aug 11. Review.

PMID:
23941829
6.

[Cellular senescence and chronic inflammation].

Ohtani N.

Nihon Rinsho Meneki Gakkai Kaishi. 2014;37(5):390-7. doi: 10.2177/jsci.37.390. Review. Japanese.

7.

Nonalcoholic steatohepatitis and noncirrhotic hepatocellular carcinoma: fertile soil.

Torres DM, Harrison SA.

Semin Liver Dis. 2012 Feb;32(1):30-8. doi: 10.1055/s-0032-1306424. Epub 2012 Mar 13. Review.

PMID:
22418886
8.

Nonalcoholic fatty liver disease, metabolic risk factors, and hepatocellular carcinoma: an open question.

Streba LA, Vere CC, Rogoveanu I, Streba CT.

World J Gastroenterol. 2015 Apr 14;21(14):4103-10. doi: 10.3748/wjg.v21.i14.4103. Review.

9.

Linking nonalcoholic fatty liver disease to hepatocellular carcinoma: from bedside to bench and back.

Yilmaz Y, Colak Y, Kurt R, Senates E, Eren F.

Tumori. 2013 Jan-Feb;99(1):10-6. doi: 10.1700/1248.13781. Review.

PMID:
23548993
10.

Histopathology of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.

Takahashi Y, Fukusato T.

World J Gastroenterol. 2014 Nov 14;20(42):15539-48. doi: 10.3748/wjg.v20.i42.15539. Review.

11.

Nonalcoholic steatohepatitis.

Brunt EM.

Semin Liver Dis. 2004 Feb;24(1):3-20. Review.

PMID:
15085483
12.

HCC and NASH: how strong is the clinical demonstration?

Rosmorduc O, Fartoux L.

Clin Res Hepatol Gastroenterol. 2012 Jun;36(3):202-8. doi: 10.1016/j.clinre.2011.12.011. Epub 2012 Feb 10. Review.

PMID:
22326764
13.

[Two cases of patients with hepatocellular carcinoma (HCC) that developed in cryptogenic cirrhosis suggestive of nonalcoholic steatohepatitis (NASH) as background liver disease after clinical courses of 26 years].

Tsutsumi K, Nakayama H, Sakai Y, Kojima Y, Dairaku N, Ojima T, Kusano M, Ikeya S, Sugai Y, Hiwatashi N.

Nihon Shokakibyo Gakkai Zasshi. 2007 May;104(5):690-7. Japanese.

PMID:
17485950
14.

The epidemiology of nonalcoholic fatty liver disease in adults.

Clark JM.

J Clin Gastroenterol. 2006 Mar;40 Suppl 1:S5-10. Review.

PMID:
16540768
15.

Non-alcoholic steatohepatitis and cancer.

Bugianesi E.

Clin Liver Dis. 2007 Feb;11(1):191-207, x-xi. Review.

PMID:
17544979
16.

The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis.

Ascha MS, Hanouneh IA, Lopez R, Tamimi TA, Feldstein AF, Zein NN.

Hepatology. 2010 Jun;51(6):1972-8. doi: 10.1002/hep.23527.

PMID:
20209604
17.

[Fatty liver and global cardiometabolic risk].

Szollár L.

Orv Hetil. 2010 Nov 21;151(47):1946-50. doi: 10.1556/OH.2010.29003. Review. Hungarian.

PMID:
21071306
18.

[Non invasive markers of non-alcoholic steatohepatitis].

Raszeja-Wyszomirska J, Miezyńska-Kurtycz J, Marlicz W, Ławniczak M, Milkiewicz P.

Pol Merkur Lekarski. 2008 Aug;25(146):166-70. Review. Polish.

PMID:
18942340
19.

Hepatocellular carcinoma in patients with non-alcoholic fatty liver disease.

Wong CR, Nguyen MH, Lim JK.

World J Gastroenterol. 2016 Oct 7;22(37):8294-8303. Review.

20.

Iron overload in nonalcoholic steatohepatitis.

Fujita N, Takei Y.

Adv Clin Chem. 2011;55:105-32. Review.

PMID:
22126026

Supplemental Content

Support Center